Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics

Vaccine

Volumn 37, Issue 50, 2019, Pages 7394-7395

  Vekemans, Johan ^a   Moorthy, Vasee ^a   Giersing, Brigitta ^a   Friede, Martin ^a   Hombach, Joachim ^a   Arora, Narendra ^b   Modjarrad, Kayvon ^c   Smith, Peter G ^d   Karron, Ruth ^e   Graham, Barney ^f   Kaslow, David C ^g  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b INCLEN Institute of Global Health ^*  (India)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g PATH   (United States)

Author keywords

Maternal immunization; Research and development; Respiratory syncytial virus; Vaccines

Indexed keywords

RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

ALGORITHM; CONSULTATION; DECISION MAKING; DISEASE BURDEN; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESEARCH; HEALTH CARE SYSTEM; HIGH RISK POPULATION; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFORMATION PROCESSING; LOW INCOME COUNTRY; MIDDLE INCOME COUNTRY; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; VACCINATION; WORLD HEALTH ORGANIZATION; BIOSYNTHESIS; FEMALE; IMMUNIZATION; IMMUNOLOGY; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; PATHOGENICITY; PATIENT SAFETY; PREGNANCY; PROCEDURES; RESPIRATORY SYSTEM; TECHNOLOGY; VIROLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; BIOMEDICAL RESEARCH; FEMALE; HUMANS; IMMUNIZATION; PATIENT SAFETY; PREGNANCY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY SYSTEM; TECHNOLOGY TRANSFER;

EID: 85040909768     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.09.092     Document Type: Review

References (5)

1. Shi, T., et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 390 (2017), 946–958.
2. Higgins, D., Trujillo, C., Keech, C., Advances in RSV vaccine research and development – A global agenda. Vaccine 34 (2016), 2870–2875.
3. http://www.who.int/immunization/research/development/ppc_rsv_vaccines/en/.
4. Kim, H., Canchola, J., Brandt, C., Pyles, G., Chanock, R., Jensen, K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89 (1969), 422–434.
5. Collins, P., Fearns, R., Graham, B., Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol 372 (2013), 3–38.